All In Biotech

Drug Trial Radar · NCT02914938

A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma

A Three-Arm Study of ME-401 Monotherapy in Subjects With Relapsed/Refractory CLL, SLL, or FL, of ME-401 in Combination With Rituximab in Subjects With Relapsed/Refractory CLL/SLL or B-cell NHL, and of ME-401 in Combination With Zanubrutinib in Subjects With Relapsed/Refractory CLL/SLL or B-cell NHL

Last checked: Nov 19, 2026Latest source record: May 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

97

Actual

Start

Oct 2016

Primary completion

Mar 29, 2023

Study completion Mar 29, 2023

Sponsor

Lead sponsor
MEI Pharma, Inc.Industry
Sponsor type
Industry
First posted
Sep 26, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Three-Arm Study of ME-401 in Subjects with Relapsed/Refractory CLL/SLL or FL, of ME-401 in Combination with Rituximab in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL, and of ME-401 in Combination with Zanubrutinib in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL

Conditions

  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)
  • Follicular Lymphoma (FL)
  • Marginal Zone B Cell Lymphoma
  • Diffuse Large B-cell Lymphoma (DLBCL)
  • High Grade Non-Hodgkin's Lymphoma
  • Mantle Cell Lymphoma (MCL)

Interventions

  • ME-401Drug

    60 mg

  • RituximabDrug

    IV infusion 375 mg/m2

  • ZanubrutinibDrug

    80 and 160 mg bid

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Minimum Biologically Effective Dose (mBED) of ME-401 aloneTime frame: 1 year
  2. Maximally Tolerated Dose (MTD) of ME-401 aloneTime frame: 1 year
  3. Dose Limiting Toxicities (DLTs) of ME-401 aloneTime frame: within the first 56 days
  4. Evaluate the safety and tolerability of ME-401 plus rituximabTime frame: 1 year
  5. Determine the MTD of ME-401 plus zanubrutinibTime frame: 1 year
  6. Determine the DLTs of ME-401 plus zanubrutinibTime frame: within the first 56 days
  7. Evaluate the safety and tolerability of ME-401 plus zanubrutinibTime frame: 1 year

Locations

24 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Arizona

    Tucson, Arizona

  • Compassionate Care

    Corona, California

  • Sylvester Comprehensive Cancer Center (Univ of Miami School of Med)

    Miami, Florida

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts

  • Dana Farber

    Boston, Massachusetts

  • Memorial Sloan Kettering

    Basking Ridge, New Jersey

  • Memorial Sloan Kettering

    Middletown, New Jersey

  • Memorial Sloan Kettering

    Montvale, New Jersey

  • Memorial Sloan Kettering

    Commack, New York

  • Memorial Sloan Kettering

    Harrison, New York

  • NYU Langone Laura & Isaac - Perlmutter Cancer Center

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Stony Brook

    Stony Brook, New York

  • Memorial Sloan Kettering

    Uniondale, New York

  • Cleveland Clinic

    Cleveland, Ohio

  • Stephenson Cancer Center

    Oklahoma City, Oklahoma

  • Vanderbilt

    Nashville, Tennessee

  • University of Southwestern Medical Center

    Dallas, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • Swedish Cancer Institute

    Edmonds, Washington

  • Swedish Cancer Institute

    Issaquah, Washington

  • Swedish Cancer Center

    Seattle, Washington

  • Carbone Cancer Center

    Madison, Wisconsin

  • lstituto Oncologico della Svizzera ltaliana Ospedale Regionale Bellinzona e Valli CH

    Bellinzona, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.